This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory").
The Center for Precision Medicine for High-risk Pediatric Cancer Frontier Program builds upon ongoing precision medicine efforts across CHOP departments to define and expand treatment options.
The Grohar Laboratory uses a bench-to-bedside-and-back approach to develop targeted therapies for pediatric solid tumors with a primary focus on the therapeutic targeting of EWS-FLI1 for Ewing sarcoma.
This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy.
Dr. Grohar is a pediatric oncologist and physician-scientist focused on the development of novel molecularly targeted therapies for pediatric solid tumors.
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.